Published in Cancer Res on July 15, 1988
Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One (2009) 1.75
Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol (2010) 1.55
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev (2009) 1.54
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer (1999) 1.50
Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression. J Control Release (2013) 1.42
Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother (2006) 1.28
Exploiting replicative stress to treat cancer. Nat Rev Drug Discov (2015) 1.27
Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Neoplasia (2009) 1.15
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer (2003) 1.12
Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol (2013) 1.11
Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br J Cancer (2000) 1.02
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest New Drugs (2010) 1.01
Pharmacogenomics of human ABC transporter ABCC11 (MRP8): potential risk of breast cancer and chemotherapy failure. Anticancer Agents Med Chem (2010) 0.99
A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer (1996) 0.97
Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells. Transl Oncol (2008) 0.96
Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study. Br J Cancer (2002) 0.94
MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann Surg Oncol (2011) 0.93
1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer (2010) 0.92
The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer (1993) 0.92
Gemcitabine functions epigenetically by inhibiting repair mediated DNA demethylation. PLoS One (2010) 0.88
Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer. Oncotarget (2014) 0.87
Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets (2012) 0.86
Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. Cancer Chemother Pharmacol (2007) 0.86
Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. Br J Clin Pharmacol (2007) 0.86
Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells. Cancer Chemother Pharmacol (2013) 0.86
Gene set analysis of purine and pyrimidine antimetabolites cancer therapies. Pharmacogenet Genomics (2011) 0.86
5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors. Bioorg Med Chem (2013) 0.85
Activation of c-Jun NH2-terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells. FEBS Lett (2005) 0.84
Gemcitabine intercellular diffusion mediated by gap junctions: new implications for cancer therapy. Mol Cancer (2010) 0.83
Synthesis and biological activity of a gemcitabine phosphoramidate prodrug. J Med Chem (2007) 0.83
Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenet Genomics (2012) 0.83
Combination studies with gemcitabine in the treatment of non-small-cell lung cancer. Br J Cancer (1998) 0.83
Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo. Br J Cancer (2014) 0.82
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine. BMC Cancer (2013) 0.82
Pharmacogenetics of human ABC transporter ABCC11: new insights into apocrine gland growth and metabolite secretion. Front Genet (2013) 0.81
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. Br J Cancer (2005) 0.81
Synthesis and restriction enzyme analysis of oligodeoxyribonucleotides containing the anti-cancer drug 2',2'-difluoro-2'-deoxycytidine. Nucleic Acids Res (1992) 0.81
Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines. BMC Genomics (2014) 0.81
Chitosan and glyceryl monooleate nanostructures containing gemcitabine: potential delivery system for pancreatic cancer treatment. AAPS PharmSciTech (2010) 0.81
Modulation of the metabolism of beta-L-(-)-2',3'-dideoxy-3'-thiacytidine by thymidine, fludarabine, and nitrobenzylthioinosine. Antimicrob Agents Chemother (1997) 0.80
Induction of pancreatic cancer cell apoptosis and enhancement of gemcitabine sensitivity by RAP80 siRNA. Dig Dis Sci (2012) 0.80
Antimetabolite Treatment for Pancreatic Cancer. Chemotherapy (Los Angel) (2014) 0.79
Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells. Cancer Biol Ther (2012) 0.79
New insights into the synergism of nucleoside analogs with radiotherapy. Radiat Oncol (2013) 0.78
Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase. Cancer Chemother Pharmacol (2010) 0.78
Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs (2013) 0.78
Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine. J Biol Chem (2014) 0.77
Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management. Pharmgenomics Pers Med (2010) 0.77
siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine. Oncotarget (2015) 0.77
Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer. Cancer Lett (2015) 0.76
Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team. Br J Cancer (1998) 0.75
Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis. Oncologist (2015) 0.75
Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials. Diagn Pathol (2014) 0.75
Drug metabolism and homologous recombination repair in radiosensitization with gemcitabine. Radiat Res (2015) 0.75
Synthesis and cytostatic evaluation of 4-N-alkanoyl and 4-N-alkyl gemcitabine analogues. J Med Chem (2013) 0.75
Nephrotic syndrome associated with gemcitabine use in a patient with ovarian cancer. Am J Case Rep (2012) 0.75
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group. BMC Cancer (2014) 0.75
Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells. BMC Genomics (2016) 0.75
Genetic factors affecting patient responses to pancreatic cancer treatment. Ann Gastroenterol (2016) 0.75
Lack of cross-resistance to FF-10501, an inhibitor of inosine-5'-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell lines. Pharmacol Res Perspect (2016) 0.75
Overexpression of karyopherin-a2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins. Oncotarget (2017) 0.75
In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2'-deoxy-2'-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models. Mol Imaging Biol (2017) 0.75
Colour junctions as predictors of radiosensitivity: X-irradiation combined with gemcitabine in a lung carcinoma cell line. J Cancer Res Clin Oncol (2003) 0.75
Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res (1991) 3.57
Superoxide dismutase as a target for the selective killing of cancer cells. Nature (2000) 3.44
Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res (1990) 2.39
Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. Int J Radiat Oncol Biol Phys (1996) 2.11
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma (2002) 2.04
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. Mol Pharmacol (1990) 1.88
Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. J Natl Cancer Inst (1975) 1.72
DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res (2001) 1.71
Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res (1993) 1.67
Selective action of 3'-azido-3'-deoxythymidine 5'-triphosphate on viral reverse transcriptases and human DNA polymerases. J Biol Chem (1990) 1.60
Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene (2008) 1.51
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res (1990) 1.50
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol (2001) 1.47
Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. Cancer Res (1992) 1.40
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol (1993) 1.38
A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem (1992) 1.38
Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol (1995) 1.38
Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia (1996) 1.36
Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol (1991) 1.33
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood (1989) 1.29
Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res (1994) 1.25
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. Mol Pharmacol (2001) 1.22
Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol (1992) 1.22
Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood (1997) 1.20
In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res (1995) 1.20
Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol (1995) 1.20
Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res (1995) 1.19
Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem (1990) 1.17
Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood (1993) 1.16
S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res (2001) 1.13
Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res (1999) 1.11
Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res (2001) 1.09
Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res (1987) 1.08
Inhibition of growth rate and deoxynucleoside triphosphate concentrations in cultured leukemia L1210 cells. Mol Pharmacol (1976) 1.06
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood (1996) 1.06
Two approaches that increase the activity of analogs of adenine nucleosides in animal cells. Cancer Res (1975) 1.06
Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol (1998) 1.06
Penetration of mouse fibroblasts by the 5'-phosphate of 9-beta-D-arabinofuranosyladenine and incorporation of the nucleotide into DNA. Proc Natl Acad Sci U S A (1974) 1.06
Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine. Biochem Pharmacol (1992) 1.06
Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res (1990) 1.05
Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia (2000) 1.04
Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J Biol Chem (2000) 1.03
Induction of apoptosis by gemcitabine. Semin Oncol (1995) 1.03
Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol (2000) 1.02
Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Semin Oncol (1987) 1.02
Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res (1988) 1.01
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood (1993) 1.01
The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res (1994) 1.00
Selective action of 2',3'-didehydro-2',3'-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases. J Biol Chem (1992) 0.99
Micro procedure for determination of pyrophosphate and orthophosphate. Anal Biochem (1970) 0.98
9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol (1986) 0.97
Sulfonimidamide analogs of oncolytic sulfonylureas. J Med Chem (1997) 0.96
Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol (1998) 0.96
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood (1993) 0.96
Effect of 2',2'-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncol Res (1992) 0.96
Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol (1996) 0.96
Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma (1993) 0.95
Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res (1980) 0.95
Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid. Cancer Res (1996) 0.95
A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors. Cancer Res (1994) 0.95
Cytotoxicity and antitumor activity of 2',2'-difluorodeoxycytidine (Gemcitabine). Cancer Invest (1990) 0.94
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res (1995) 0.94
Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res (1980) 0.94
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia (2006) 0.92
Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance. Mol Pharmacol (1997) 0.92
Characterization of the intracellular distribution and binding in human adenocarcinoma cells of N-(4-azidophenylsulfonyl)-N'-(4-chlorophenyl)urea (LY219703), a photoaffinity analogue of the antitumor diarylsulfonylurea sulofenur. Biochem Pharmacol (1995) 0.92
Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine. Cancer Chemother Pharmacol (1996) 0.91
Evaluation of ribonucleoside and deoxyribonucleoside triphosphate pools in cultured leukemia cells during exposure to methotrexate or methotrexate plus thymidine. Cancer Res (1979) 0.91
Biochemical pharmacology of penclomedine (NSC-338720). Biochem Pharmacol (1995) 0.90
Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res (2000) 0.90
Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res (1997) 0.89
MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Leukemia (2011) 0.89
Membrane-permeable dideoxyuridine 5'-monophosphate analogue inhibits human immunodeficiency virus infection. Mol Pharmacol (1992) 0.89
High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatogr B Biomed Sci Appl (2000) 0.89
Isolation of a DNA polymerase alpha-associated regulatory protein from calf thymus. Cancer Res (1979) 0.89
Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs (1996) 0.89
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma (1993) 0.89
Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. J Clin Oncol (1998) 0.89
Design of new anticancer therapies targeting cell cycle checkpoint pathways. Curr Opin Oncol (2001) 0.88
Biochemical and pharmacological effects of the fermentation-derived antitumor agent, (alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125). Cancer Res (1979) 0.88
Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res (1996) 0.88
Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res (1973) 0.88
Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol (1995) 0.88
Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC). Biochem Pharmacol (2001) 0.87
Sulfonylureas: a new class of cancer chemotherapeutic agents. J Med Chem (1992) 0.87
Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues. J Med Chem (1989) 0.87